Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation induction

Table 4 Duration of recombinant human follicle-stimulating hormone (r-hFSH) stimulation and total and daily r-hFSH doses required - primary efficacy analysis population (patients who received hCG injections)

	CLD group	LD group	Total	p
	(n = 94)	(n = 91)	(N = 185)	p
Duration of stimulation, days	13.7 +/− 6.33	12.9 +/− 5.58	13.3 +/− 5.97	0.36
Daily dose, IU	78.7 +/− 8.90	85.0 +/− 15.35	81.8 +/− 12.86	<0.001
Total dose, IU	1119.4 +/− 690.04	1155.5 +/− 730.45	1137.2 +/− 708.50	0.73

Data are mean +/− standard deviation.
p values show the difference between treatment groups using analysis of variance.
Values in bold are significant.
CLD = chronic low-dose; hCG = human chorionic gonadotrophin; LD = low-dose.

ISSN: 1477-7827